Rallybio Corp Stock Today
| RLYB Stock | USD 0.74 0.04 5.71% |
PerformanceVery Weak
| Odds Of DistressLow
|
Rallybio Corp is trading at 0.74 as of the 26th of February 2025, a 5.71% increase since the beginning of the trading day. The stock's open price was 0.7. Rallybio Corp has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of July 2021 | Category Healthcare | Classification Health Care |
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. The company has 41.49 M outstanding shares of which 350.19 K shares are at this time shorted by private and institutional investors with about 6.15 trading days to cover. More on Rallybio Corp
Moving against Rallybio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Rallybio Stock Highlights
| CoFounder Chairman | Martin MacKay | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRallybio Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Rallybio Corp's financial leverage. It provides some insight into what part of Rallybio Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Rallybio Corp (RLYB) is traded on NASDAQ Exchange in USA. It is located in 234 Church Street, New Haven, CT, United States, 06510 and employs 25 people. Rallybio Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.04 M. Rallybio Corp conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.49 M outstanding shares of which 350.19 K shares are at this time shorted by private and institutional investors with about 6.15 trading days to cover.
Rallybio Corp currently holds about 147.37 M in cash with (60.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Rallybio Corp Probability Of Bankruptcy
Ownership AllocationRallybio Corp owns a total of 41.49 Million outstanding shares. The majority of Rallybio Corp outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Rallybio Corp to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Rallybio Corp. Please pay attention to any change in the institutional holdings of Rallybio Corp as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Rallybio Ownership Details
Rallybio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Laurion Capital Management Lp | 2024-12-31 | 735.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 441.3 K | |
| Mariner Wealth Advisors Llc | 2024-12-31 | 404.5 K | |
| Millennium Management Llc | 2024-12-31 | 338.9 K | |
| Geode Capital Management, Llc | 2024-12-31 | 247.8 K | |
| Blackrock Inc | 2024-12-31 | 201.2 K | |
| Northeast Financial Consultants, Inc | 2024-12-31 | 96.4 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 91.6 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 91.3 K | |
| Viking Global Investors Lp | 2024-12-31 | 4.2 M | |
| Johnson & Johnson | 2024-12-31 | 3.6 M |
Rallybio Corp Historical Income Statement
Rallybio Stock Against Markets
Rallybio Corp Corporate Executives
Elected by the shareholders, the Rallybio Corp's board of directors comprises two types of representatives: Rallybio Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rallybio. The board's role is to monitor Rallybio Corp's management team and ensure that shareholders' interests are well served. Rallybio Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rallybio Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan MBA | CFO Treasurer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rallybio Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rallybio Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.